Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature

BMC Infect Dis. 2014 Sep 23:14:514. doi: 10.1186/1471-2334-14-514.

Abstract

Background: Prolonged asymptomatic carriage of vancomycin-resistant enterococci (VRE) in the gastrointestinal tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings.

Case presentation: We report a regimen for decolonization of gastrointestinal carriage of VRE by a combination of environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any remaining VRE, and subsequent oral Lactobacillus rhamnosus GG to maintain the colonization resistance in four patients, including two patients with end-stage liver cirrhosis, one patient with complication post liver transplant, and one patient with complicated infective endocarditis. All patients had clearance of VRE immediately after decolonization, and 3 of them remained VRE-free for 23 to 137 days of hospitalization, despite subsequent use of intravenous broad-spectrum antibiotics without anti-VRE activity.

Conclusion: This strategy should be further studied in settings of low VRE endemicity with limited isolation facilities.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Carrier State / microbiology
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Cross Infection / prevention & control*
  • Enterococcus faecium / drug effects
  • Enterococcus faecium / growth & development*
  • Female
  • Gastrointestinal Tract / microbiology*
  • Gram-Positive Bacterial Infections / drug therapy
  • Gram-Positive Bacterial Infections / microbiology
  • Gram-Positive Bacterial Infections / prevention & control*
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Vancomycin Resistance*

Substances

  • Anti-Bacterial Agents